Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Risk & Volatility
Bayer Aktiengesellschaft has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.57, meaning that its share price is 257% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Bayer Aktiengesellschaft and Scienture, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bayer Aktiengesellschaft | 0 | 1 | 5 | 2 | 3.12 |
| Scienture | 1 | 1 | 1 | 0 | 2.00 |
Scienture has a consensus price target of $6.00, suggesting a potential upside of 106.90%. Given Scienture’s higher probable upside, analysts plainly believe Scienture is more favorable than Bayer Aktiengesellschaft.
Insider & Institutional Ownership
5.7% of Scienture shares are held by institutional investors. 19.5% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Bayer Aktiengesellschaft and Scienture’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bayer Aktiengesellschaft | -3.12% | 16.10% | 4.27% |
| Scienture | N/A | -53.51% | -42.47% |
Valuation & Earnings
This table compares Bayer Aktiengesellschaft and Scienture”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bayer Aktiengesellschaft | $51.55 billion | 1.19 | -$4.10 billion | ($0.42) | -37.29 |
| Scienture | $430,000.00 | 11.87 | -$41.51 million | ($52.50) | -0.06 |
Scienture has lower revenue, but higher earnings than Bayer Aktiengesellschaft. Bayer Aktiengesellschaft is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Summary
Scienture beats Bayer Aktiengesellschaft on 8 of the 15 factors compared between the two stocks.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft is a German life sciences company headquartered in Leverkusen. Founded in 1863, it develops products and services in pharmaceuticals, consumer health and agriculture. Its Pharmaceuticals business offers prescription medicines, including treatments in areas such as cardiovascular disease, oncology, women’s health and eye care. Consumer Health sells nonprescription medicines and self-care products, with brands including Claritin, Aleve and One A Day. Through its Crop Science business, Bayer provides seeds, crop protection products and agricultural solutions for farmers.
About Scienture
Scienture is a specialty pharmaceutical company focused on developing and commercializing prescription treatments, particularly for central nervous system disorders. Its work includes advancing medicines and drug-delivery formulations intended to address patient needs in these areas. The company’s portfolio has included ZolpiMist, an FDA-approved zolpidem tartrate oral spray used to treat insomnia. Scienture has focused primarily on the U.S. pharmaceutical market.
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
